Table 2. Summary of the DeWorm3 field trials.

Study Design:	Community cluster randomized controlled trial
Intervention:	Twice-annual community-wide MDA of albendazole for 3 years delivered to all individuals over 24 months of age
Control:	Targeted MDA of PSAC and SAC with albendazole for 3 years delivered in accordance with national MOH guidelines
Primary Outcome:	Transmission interruption of STH species (weighted prevalence ≤2% 24 months following the final round of MDA)
MDA eligibility criteria:	A PSAC or SAC residing in a control cluster OR any resident in an intervention cluster Eligible for treatment with albendazole according to WHO and national guidelines
MDA exclusion criteria:	Children under one or two years of age, depending on national guidelines Women in the first trimester of pregnancy History of adverse reaction to benzimidazoles Acutely ill at the time of MDA
Sampling eligibility criteria:	Residents of the study cluster based on census and questionnaire responses Provide consent and/or assent (as applicable)
Sampling exclusion criteria:	Individuals who do not reside in the study cluster Refusal to consent/assent Enrollees in the longitudinal monitoring cohort ineligible for inclusion in cross-sectional sampling
Sampling schedule:	Cross-sectional sampling of randomly selected eligible participants will take place at baseline (pre-MDA), post-treatment (six months following the final round of MDA), and at endline (24 months following the final round of MDA) Longitudinal monitoring cohorts will be sampled annually